Abstract:Cullin-RING E3 ligases (CRLs) are the major components of ubiquitin-proteasome system, responsible for ubiquitylation and subsequent degradation of thousands of cellular proteins. CRLs play vital roles in the regulation of multiple cellular processes, including cell cycle, cell apoptosis, DNA replication, signalling transduction among the others, and are frequently dysregulated in many human cancers. The discovery of specific neddylation inhibitors, represented by MLN4924, has validated CRLs as promising targets for anti-cancer therapies with a growing market. Recent studies have focused on the discovery of the CRLs inhibitors by a variety of approaches, including high through-put screen, virtual screen or structure-based drug design. The field is, however, still facing the major challenging, since CRLs are a large multi-unit protein family without typical active pockets to facilitate the drug design, and enzymatic activity is mainly dependent on undruggable protein-protein interactions and dynamic conformation changes. Up to now, most reported CRLs inhibitors are aiming at targeting the F-box family proteins (e.g., SKP2, β-TrCP and FBXW7), the substrate recognition subunit of SCF E3 ligases. Other studies reported few small molecule inhibitors targeting the UBE2M-DCN1 interaction, which specifically inhibits CRL3/CRL1 by blocking the cullin neddylation. On the other hand, several CRL activators have been reported, such as plant auxin and immunomodulatory imide drugs, thalidomide. Finally, proteolysis-targeting chimeras (PROTACs) has emerged as a new technology in the field of drug discovery, specifically targeting the undruggable protein-protein interaction. The technique connects the small molecule that selectively binds to a target protein to a CRL E3 via a chemical linker to trigger the degradation of target protein. The PROTAC has become a hotspot in the field of E3-ligase-based anti-cancer drug discovery.

Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Targeting Cullin-RING E3 ligases for anti-cancer therapy:efforts on drug discovery

Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation

Cullin-RING Ligases as attractive anti-cancer targets.

Targeted protein degradation: expanding the toolbox

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges

PROTACs: A Novel Strategy for Cancer Drug Discovery and Development

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Bivalent Ligands for Protein Degradation in Drug Discovery

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs

E3 ligase ligand optimization of Clinical PROTACs

Small Molecule PROTACs: an Emerging Technology for Targeted Therapy in Drug Discovery

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

The Application Of Ubiquitin Ligases In The Protac Drug Design

E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones

Computational Strategies for PROTAC Drug Discovery

Current Advances of Small Molecule E3 Ligands for Proteolysis-Targeting Chimeras Design

Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications

The emerging role for Cullin 4 family of E3 ligases in tumorigenesis